TABLE 1A from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
posted on 2023-08-08, 14:20authored byBrian J. Francica, Anja Holtz, Justine Lopez, David Freund, Austin Chen, Dingzhi Wang, David Powell, Franciele Kipper, Dipak Panigrahy, Raymond N. Dubois, Chan C. Whiting, Peppi Prasit, Thomas W. Dubensky
Prostaglandin pathway inhibitor drugs
Funding
Tempest Therapeutics
History
ARTICLE ABSTRACT
Prostaglandin (PGE2) drives tumor progression but the pathway has not been effectively drugged. We demonstrate significantly enhanced immunologic potency and antitumor activity through blockade of EP2 and EP4 PGE2 receptor signaling together with a single molecule.